Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.

Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS.

J Mol Diagn. 2006 May;8(2):209-17.

2.

CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS.

Gut. 2006 Jul;55(7):1000-6. Epub 2006 Jan 11.

3.

Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study.

Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS.

J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94.

PMID:
16288122
4.

Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side.

Samoha S, Arber N.

Oncology. 2005;69 Suppl 1:33-7. Epub 2005 Sep 19. Review.

PMID:
16210875
5.

Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers.

Ebert MP, Mooney SH, Tonnes-Priddy L, Lograsso J, Hoffmann J, Chen J, Röcken C, Schulz HU, Malfertheiner P, Lofton-Day C.

Neoplasia. 2005 Aug;7(8):771-8.

6.

MGMT promoter methylation and field defect in sporadic colorectal cancer.

Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP.

J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8.

PMID:
16174854
7.

DNA methylation, field effects, and colorectal cancer.

Giovannucci E, Ogino S.

J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9. No abstract available.

PMID:
16174847
8.

Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.

Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, Pinchuk I, Marian B, Lichtenberg D, Arber N.

Clin Cancer Res. 2005 Sep 15;11(18):6738-44.

9.

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.

Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS.

Clin Cancer Res. 2005 Sep 15;11(18):6650-6.

10.

Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.

Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML.

Gastroenterology. 2005 Sep;129(3):837-45.

PMID:
16143123
11.

Serrated adenoma of the colorectum and the DNA-methylator phenotype.

Jass JR.

Nat Clin Pract Oncol. 2005 Aug;2(8):398-405. Review.

PMID:
16130936
12.

Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component.

Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS.

Mod Pathol. 2006 Jan;19(1):59-68.

13.

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS.

J Mol Diagn. 2005 Aug;7(3):413-21.

14.

Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers.

Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML.

Cancer Res. 2005 Jul 15;65(14):6063-9.

15.

Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival.

Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P.

Clin Cancer Res. 2005 Jul 1;11(13):4754-60.

16.

Colorectal cancer "methylator phenotype": fact or artifact?

Anacleto C, Leopoldino AM, Rossi B, Soares FA, Lopes A, Rocha JC, Caballero O, Camargo AA, Simpson AJ, Pena SD.

Neoplasia. 2005 Apr;7(4):331-5.

17.

The Nurses' Health Study: lifestyle and health among women.

Colditz GA, Hankinson SE.

Nat Rev Cancer. 2005 May;5(5):388-96. Review.

PMID:
15864280
18.

COX-2: a molecular target for colorectal cancer prevention.

Brown JR, DuBois RN.

J Clin Oncol. 2005 Apr 20;23(12):2840-55. Review.

PMID:
15837998
19.

Cancer epigenetics.

Laird PW.

Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65-76. Review.

PMID:
15809275
20.

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.

Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN.

J Clin Oncol. 2005 Jan 10;23(2):254-66. Review.

PMID:
15637389

Supplemental Content

Support Center